CA125 expression in patients with non-Hodgkin's lymphoma

The present study investigated the possible clinical significance of serum CA125 levels in patients with non-Hodgkin's lymphoma (NHL) and the mechanism of secretion. Serum CA125 levels in 335 patients with NHL were measured by enzyme-linked immunosorbent assay. The tissue CA125 expression in 22 patients with NHL was performed on paraffin section by immunohistochemical methods. One hundred and ninety-eight cases (59.1%) were found to have elevated serum CA125 levels. Serum CA125 levels were associated with clinical stage, effusions, high serum lactate dehydrogenase and beta2-M levels, and response to therapy. Microscopically, immunohistochemical staining revealed that malignant tumor cells demonstrated negative CA125 expression in all of the 22 cases. Our results suggested that serum CA125 levels could be an interesting tumor marker in NHL. The immunohistochemical study suggested that CA125 appeared not to be secreted by lymphoma cells directly.     

Prognostic determinants in epithelioid sarcoma

Background

Epithelioid sarcoma (ES) is a rare soft tissue neoplasm that usually arises in the distal extremities of young adults, presents a high rate of recurrences and metastases and frequently poses diagnostic dilemmas. In order to identify markers useful for patient stratification purposes, we investigated the prognostic impact of clinical and molecular patient characteristics, including the status of SMARCB1 tumour suppressor gene, in a consecutive series of ES cases.

Methods

Kaplan-Meier survival curves were compared by the log-rank test. Immunophenotyping and SMARCB1 protein expression were analysed by immunohistochemistry or western blotting in 40 ES patients for which tumour material was available. Cases lacking SMARCB1 protein expression were investigated for the presence of gene mutations and gene deletions by exon sequencing, fluorescent in situ hybridization and quantitative PCR.

Results

FNCLCC tumour grade 3 and proximal-type histology significantly correlated with shorter overall survival (log-rank p = 0.0046 and p = 0.0001, respectively). We identified loss of SMARCB1 protein expression in the majority of ES cases (25/40, 62.5%), including 24/34 (71%) adult cases but only 1/6 (17%) paediatric/adolescent cases (p = 0.02, two-tailed Fisher’s exact test). The absence of protein is strongly correlated with SMARCB1 gene deletion (p = 0.003, two-tailed Fisher’s exact test). We observed a trend towards the correlation between SMARCB1 inactivation and both higher tumour grading and a clinical course of the disease characterised by the occurrence of multiple relapses/metastasis.

Conclusion

These data show that both tumour grading and subtype are prognostic factors in ES. Loss of SMARCB1 protein expression in ES is a frequent occurrence mediated by gene deletion events, thus pointing to a crucial role of SMARCB1 in ES genesis. Analysis of SMARCB1 status in ES warrants prospective investigation as a prognostic marker and therapeutic target.     

上皮样肉瘤的临床病理分析

目的探讨上皮样肉瘤的临床病理特征及鉴别诊断。方法复习10例上皮样肉瘤的临床病理资料,应用免疫组化进行病理形态和免疫表型分析。结果免疫组化结果显示,10例均表达细胞角蛋白(CK)和波形蛋白(Vim)阳性,上皮膜抗原(EMA)9例阳性,6例CD34阳性,S-100、平滑肌肌动蛋白(SMA)各在1例肿瘤中见局灶阳性,不表达结蛋白(Des)、肌红蛋白(MG)、FRAg、CD31、HMB45。结论上皮样肉瘤是一种分化未定免疫表型复杂的少见的软组织肿瘤,好发于肢体远端。     

上皮样肉瘤的临床病理研究

目的探讨上皮样肉瘤(ES)的临床、病理学特征及鉴别诊断要点。方法收集17例上皮样肉瘤患者资料,观察和分析其临床和组织病理学特征,通过免疫组化方法分析其细胞角蛋白(CK)、上皮膜抗原(EMA)、波形蛋白(Vimentin)、S-100蛋白、CD34及平滑肌肌动蛋白(SMA)的表达。结果 17例患者中,男性13例,女性4例,男性多见。平均年龄35.6岁。远端型6例,近心型11例。两型病理形态不同,但免疫组化表达一致,均表达CK、EMA、Vimentin和CD34。初次手术后1年、3年复发及转移率分别为50.0%(8/16)和87.5%(14/16)。结论 ES是一种极易局部复发和远处转移的恶性肿瘤,免疫组化有助于诊断及鉴别诊断。根治性手术是首选治疗方案,ES易发生淋巴结转移,区域淋巴结清扫是必要的。     

外阴上皮样肉瘤的临床分析

目的 探讨外阴上皮样肉瘤的临床特点、诊断治疗方法及预后.方法 对我院收治的4例和文献报道资料完整的16例外阴上皮样肉瘤患者进行回顾性分析.结果 20例外阴上皮样肉瘤患者年龄23～80岁,中位年龄36岁.肿物直径为1～10 cm,中位数为5.1 cm.免疫组化检测结果显示,20例外阴上皮样肉瘤患者vimentin阳性,19例CK阳性,16例EMA阳性.10例患者行双侧或同侧腹股沟淋巴结清扫,3例未行腹股沟淋巴结清扫.术后7例患者未补充治疗,13例患者行术后放疗和(或)化疗.20例外阴上皮样肉瘤患者中,无复发及转移11例(55.0%),腹股沟淋巴结转移治疗后存活2例(10.0%),死亡7例(35.0%).早期患者(Ⅰ～Ⅱ期)的中位生存时间(21个月)高于晚期患者(6个月,P＜0.05).10例行双侧或同侧腹股沟淋巴结清扫患者的中位生存时间为11.5个月,3例未行腹股沟淋巴结清扫患者的中位生存时间为6个月,差异无统计学意义(P=0.086).结论 外阴上皮样肉瘤误诊率较高,确诊时需要结合免疫组化检查,诊断上皮样肉瘤的标记性蛋白为vimentin、EMA和CK.外阴上皮样肉瘤的有效治疗方法为局部广泛切除加双侧腹股沟淋巴结清扫,手术切缘至少2 cm,化疗和放疗的疗效尚不确切.     

Va-es-bj - an epithelioid sarcoma cell-line

A tumor cell line was derived and established from a bone marrow aspirate of a 41-year-old male who presented with motor symptoms of cord compression and an epidural tumor with osseous, pulmonary and hepatic metastases. The epidural tumor was an epithelioid sarcoma staining positive for cytokeratin markers of epithelial differentiation AE-1 and AE-3. This cell line was composed of lowly refractile, multinucleated giant or mononuclear round or elongated cells with monopolar or bipolar short processes. When permitted to grow beyond confluence these cells clumped up and formed mounds progressing to free floating spheroids. The cells were characterized by chromosomal triploidy with marker chromosomes, rapid growth in nude mice and secretion of immunoreactive and biologically functional granulocyte macrophage colony stimulating factor. This epithelioid sarcoma cell line stained positive for AE-1, AE-3, vimentin, epithelial membrane antigen and was designated VA-ES-BJ.     

上皮样肉瘤的诊治分析

目的 分析上皮样肉瘤(ES)的临床特点、治疗模式及预后.方法 回顾性分析1995年3月至2008年12月间天津医科大学附属肿瘤医院收治的13例ES患者的临床资料、治疗和随访情况.其中男性10例,女性3例,平均年龄41.5岁.肿瘤发生于上肢6例,下肢4例,腰背部3例.全组除1例患者因远处血行转移行姑息化疗外,其余12例均行手术治疗.术后单纯放疗4例,单纯化疗5例,放疗+化疗1例.采用SPSS 16.0统计软件包,以Kaplan-Meier法进行生存分析.结果 13例ES患者中,12例为单发肿物,肿物平均直径为(6.07±1.34) cm;有6例(46.2％)患者发现区域淋巴结转移.10例随访患者中,5例(50.0％)出现肿瘤局部复发,3例(30.0％)出现远处转移,其中以肺转移最常见;4例患者于术后2年内死亡.全组患者术后l、2、5、10年生存率分别为72.7％、54.5％、27.3％和9.1％,中位生存时间为27个月.结论 ES临床罕见,易发生局部复发、淋巴结扩散和(或)远处转移,患者预后不佳.明确诊断需病理学检查,手术切除仍是ES的主要治疗方式.     

CA125和AFP检测对原发性肝癌诊断的比较

目的　分析CA12 5和AFP在原发性肝癌患者血清中的表达情况。　方法　采用放免分析对 6 3例原发性肝癌患者进行血清CA12 5和AFP的检测 ,统计分析两项指标的表达情况 ,并进行比较。结果　CA12 5和AFP的含量分别为 172 8± 2 0 0 5ku/L ,2 6 2 4± 2 86 3ug/L。以CA12 5 >35ku/L ,AFP>2 0ug/L为原发性肝癌诊断标准 ,其阳性率分别为 6 9 8%和 6 8 3% ,两者联合检测阳性率为 87 3%。统计学Ridit分析 ,两者表达阳性率无显著性差异 ;相关性分析 ,两者无线性相关关系存在。CA12 5和AFP单项检查的阳性率分别与联合检查的阳性率进行X2 检验 ,均有显著性差异 (P <0 0 5 )。结论　CA12 5是一项较好的原发性肝癌诊断标志物 ,与AFP阳性率无显著性差异 ,与AFP无相关性。联合检测可显著提高诊断阳性率。     

CA125在肿瘤患者细胞和血清中表达相关性的研究

目的：比较 CA125在肿瘤患者细胞和血清中的表达情况,探讨其细胞表达和血清表达有无相关性。方法：回顾性分析2014年－2015年在我院进行细胞免疫组化 CA125和血清肿瘤标志物 CA125检查的肿瘤患者136例,分析其表达情况,并应用配对卡方检验分析两种方法检查结果的相关性。结果：136例肿瘤患者, CA125检查细胞免疫组化阳性104例,血清检查 CA125阳性114例,同时阳性92例,同时阴性10例,细胞学阳性而血清学阴性12例,细胞学阴性而血清学阳性22例,配对卡方检验 P ＜0．05,两种方法差异有统计学意义。结论：CA125在细胞中的表达和血清中的表达有统计学差异,不能简单等同。     

DNA flow cytometry of epithelioid sarcoma.

DNA ploidy of paraffin-embedded tissue from 11 patients with epithelioid sarcoma and 20 control specimens (granuloma annulare and sarcoid) was studied. DNA aneuploidy was found in 64% of the epithelioid sarcomas and in none of the control samples. Aneuploidy did not correlate with necrosis, vascular invasion, or mitotic rate. There was also no association of aneuploidy with adverse outcome.     

Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential

Immunohistochemical localization of CA 125 using murine monoclonal antibody OC 125 was performed on fresh frozen tissue from 44 endometrial adenocarcinomas and 26 benign endometria. Immunohistochemical evaluation incorporated both intensity and distribution of staining (CA 125 HSCORE). Thirty-seven cancers (84%) and 23 benign endometria (88%) expressed immunohistochemically detectable CA 125. Staining was confined to epithelial cells and was present both on the cell membrane and in the cytoplasm. Among the 44 endometrial cancers, CA 125 HSCORE did not correlate with histological grade, depth of myometrial invasion or estrogen/progesterone receptor levels. Following surgical staging, 13 patients (30%) were found to have extrauterine metastatic disease. The median CA 125 HSCORE of patients with metastatic disease (2.25) was significantly higher than that of patients with disease confined to the uterus (0.6) (P less than 0.001). In addition, high CA 125 HSCORE also correlated with the presence of lymph node metastasis (P less than 0.001). The results of this study suggest that high CA 125 expression by endometrial adenocarcinomas is associated with increased metastatic potential.     

A case of epithelioid sarcoma arising in the vulva

Epithelioid sarcoma of vulva is extremely rare. Only 20 cases have been reported in the literature so far. Early diagnosis is difficult because of its benign appearance as a painless subcutaneous nodule. Therefore treatment can be delayed, although epithelioid sarcoma requires prompt surgery. We report a case of epithelioid sarcoma that occurred in the left vulva with a brief review of literature.     

上皮样肉瘤14例临床分析

背景与目的:上皮样肉瘤是一种组织起源尚不清楚的罕见软组织肉瘤.其生物学行为独特,容易发生局部复发、淋巴结扩散和/或远处转移.本研究旨在探讨上皮样肉瘤(Epithelioid sarcoma)的临床特点、诊断、治疗和预后.方法:对我院1990年1月至2005年12月间收治的14例上皮样肉瘤临床资料进行回顾性分析,并结合随访资料进行生存分析.全组14例均接受手术治疗.首次手术均在外院进行.再次手术11例在我院进行(9例行扩大切除术,2例行截肢术;4例同时行区域淋巴结清扫术),3例仍在外院行局部切除术或扩大切除术.术后9例接受辅助性治疗,其中单纯放疗6例,放疗 化疗3例.结果:全组在本院病理科复检确诊为上皮样肉瘤.12例(85.7%)出现肿瘤局部复发.4例(28.6%)发现区域淋巴结转移,9例术后3年内死亡.全组总的1、2、5、10年生存率为71.43%、55.56%、27.78%和13.89%.结论:上皮样肉瘤恶性程度并不很高,但局部复发率高,容易发生淋巴结和/或远处转移,预后不佳.广泛性切除或根治性切除合并预防性区域淋巴结清扫术是治疗上皮样肉瘤的有效手段.     

上皮样肉瘤的病理诊断与鉴别诊断

目的探讨上皮样肉瘤的病理特点及鉴别诊断。方法13例上皮样肉瘤,男9例,女4例,年龄10～45岁。病变主要位于前臂、手掌和手指。行显微镜下观察组织形态特点并结合免疫组化染色结果进行分析。结果组织学表现为肿瘤细胞由恶性上皮样细胞和梭形细胞组成,呈结节样排列并伴有中心坏死。所有瘤组织CK、EMA和Vimentin均为阳性表达。结论上皮样肉瘤无特异性症状和体征,病理学特点及鉴别诊断应紧密结合临床表现和免疫组化结果。     

Case of epithelioid sarcoma of the lower extremity

A 26-year-old woman with epithelioid sarcoma is reported. An 8 X 4 cm mass was present in the pretibial region of the right leg. The operative specimen revealed a solid mass with necrosis and hemorrhage. Histologically, the tumor consisted of large round or oval cells with rich and eosinophilic cytoplasm and many vascular invasions. Electron-microscopically, the tumor was composed of light and dark cells. The dark cells showed abundant microfibrils in their cytoplasm compared to the light cells. We posit that the tumor was of synovial cell origin because of the presence of cytoplasmic microfibrils, pinocytotic vesicles and filopodias or microvilli-like structures.     

Immunohistochemical expression of CA19-9 and CA125 in mucoepidermoid and adenoid cystic carcinomas of the salivary gland

This study examined the immunohistochemical expression of carbohydrate antigens CA19-9 and CA125 and their relationship to various biological parameters in 27 mucoepidermoid carcinomas (MEC) and 18 adenoid cystic carcinomas (ACC) arising from salivary glands. The series showed higher immunopositivity for CA125 (67% for MEC; 33% for ACC) than for CA19-9 (59% for MEC; 11% for ACC). CA19-9 epitope was mainly expressed in cystic (MEC) and cribriform/tubular (ACC) components of carcinoma tissues. Solid components in MEC occasionally showed positive staining for CA19-9. CA125 was evenly expressed in both ACC and MEC tissues regardless of their different histological components. The positive expression of CA19-9 and CA125 in the carcinoma tissues did not influence the clinical course of patients with MEC and ACC. A significant relationship was only demonstrated between the immunohistochemical expression of CA125 and the low proliferative activity (LI) evaluated by Ki-67 immunohistochemistry. However, no significant relationship was found between LI and the patients' clinical course. These results suggest that the immunostaining for CA19-9 and CA125 provide no reliable data to predict the clinical course of patients with MEC and ACC of the salivary glands.     

Treatment of epithelioid sarcoma at the royal marsden hospital

Purpose: The aim of this study was to assess treatment and outcome with respect to clinical and pathological features.Patients and methods: Thirty-nine patients were identified (range 7-66 years, mean 23). Initial treatment comprised local excision in 11 patients and wide excision in 14. Post-operative external beam radiotherapy was prescribed in 22 patients with a total dose of 60 Gy, delivered in two phases.Results: The cause-specific survival for the entire group was 79, 63, 56 and 45% at 1, 3, 5 and 10 years, respectively. A distal limb location was associated with a better prognosis than proximal limb location (P = 0.04).Conclusions: Our data favour treatment with wide functional excision followed by radical dose radiotherapy in attempt to minimize risk of local recurrence, especially when primary tumours are bigger than 3 cm. Our data also suggest the same treatment for local recurrence, when technically possible, to avoid amputation.